Important news for IntelliConnect customers

It’s no secret that technology is changing the way each of us works and Wolters Kluwer is committed to helping you harness the power of technology to drive greater efficiencies and improved outcomes for your business. As part of that commitment, we continue to invest roughly 10% of our annual revenues into the development and enhancement of new and existing products.

In 2015, based on close collaboration with our customers, we launched Cheetah™, an intuitive legal research platform, powered by Wolters Kluwer’s world-class content enabling legal professionals to quickly understand and advise on today’s complex matters. In 2018, Cheetah™ won the SIIA CODiE Award for Best Legal Solution.

Over the past year, Cheetah™ has been successfully adopted by more than 2,500 law firms, law schools, and corporate legal departments. Based on this adoption, we’ve reached the point where we have decided to sunset the IntelliConnect platform and move to one research platform, Cheetah™. This move will allow us to further invest in enhancements to Cheetah™ and other value-added solutions for the legal marketplace. As part of this change, we will migrate any remaining IntelliConnect customers to Cheetah™ over the next few months.

Your successful transition to Cheetah™ is very important to us and we are here to support you along the way. We will also provide you with dual access to your subscribed content on Cheetah™ and IntelliConnect at no additional charge at this time.

If you have questions in the meantime, please contact us at 1-800-955-5217 or CheetahSupport@wolterskluwer.com. If you would like to learn more about Cheetah™, please go to our dedicated site for Training & Support.

Thank you for being a valued customer. We greatly appreciate your patronage, and look forward to our continued partnership.

Sincerely,

Dean Sonderegger
Vice President, Legal Markets & Innovation
Legal & Regulatory, U.S.

WoltersKluwerLR.com

The Empire State woos pharma, biotech industries

The 21st Century Cures Act (Cures Act) was passed by the House on November 30, 2016 and the Senate on December 7, 2016. The President signed it into law on December 13, 2016.  The Cures Act contains three primary titles that makes good on the promise of its name through FDA reforms by accelerating drug and device development and delivery. The Cures Act also creates new administrative positions related to mental health and substance abuse and provides state funding to combat opioid addiction. The President applauded Congress’ approval of the bill, commenting, “I think it indicates the power of this issue and how deeply it touches every family across America.”

In a similar vein, New York Governor Andrew Cuomo and New York City Mayor Bill de Blasio recently unveiled two initiatives that would commit $1.15 billion in funding and tax incentives for education, business development, and job creation in the life sciences sector. Of the total amount,  New York City will be investing $500 million in biotech and life sciences over the next decade via a program called LifeSci NYC, the largest piece is composed of $300 million in tax credits that will be made available to companies building lab space in the city, in order to defray the high costs of construction in the city. The state’s contributions include $250 million in tax incentives for new and existing life science companies, $200 million in state capital grants to support investment in wet-lab and innovation space, and $100 million in investment capital for early stage life science initiatives with an additional match of at least $100 million for operating support from private sector partnerships.

Citing the lack of affordable and appropriate lab space as a barrier to industry, especially in the New York City real estate market, the state and city initiatives will provide more than 3.2 million square feet of innovation space and 1,100 acres of developable land available tax-free at 45 colleges and universities statewide. The availability of grants, land and space would offer an incentive for life science industry to access labs, infrastructure, and other equipment for product development.